Nautilus Biotechnolgy, Inc.
$1.19 -$0.50 (-29.88%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
A material event was filed (Form 8-K).
8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
From its Mar 24 high, the share price fell 58%.
Peak close $3.95 on Mar 24; trough close $1.64 on Jul 16. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -58% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 23
The stock moved +19.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 23 -
Feb 17
The stock moved +22.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 17
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Nautilus Biotechnolgy, Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.